Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-05-22

Innoviva (INVA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$5,400,197
Pavel Raifeld total, FY2025
47th
CEO pay percentile vs peers
12.3:1
CEO-to-median pay ratio
94.95%
Say-on-pay support, latest vote
Companies that benchmark against INVA
4 companies name INVA as a compensation peer

Each company listed discloses INVA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INVA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Pavel Raifeld$600,000$378,000$2,649,982$1,748,882$0$0$23,333$5,400,197
Chief Executive Officer
Stephen Basso475,000223,493691,087765,3480018,3482,171,276
Chief Financial Officer and President of IST
Marianne Zhen420,000245,438161,599229,9890025,8331,082,859
Chief Accounting Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Pavel Raifeld$5,400,197
Stephen Basso2,171,276
Marianne Zhen1,082,859

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Derek A. SmallDirector2026-05-04A9,786$0$0CommonForm 4 ↗
Sarah J. SchlesingerDirector2026-05-04A9,78600CommonForm 4 ↗
Jules HaimovitzDirector2026-05-04A9,78600CommonForm 4 ↗
Stephen BassoChief Financial Officer2026-05-04A37,99400CommonForm 4 ↗
Sarah J. SchlesingerDirector2026-05-04A10,00000Derivative, Class A CommonForm 4 ↗
Marianne ZhenChief Accounting Officer2026-05-04A31,50000Derivative, Class A CommonForm 4 ↗
Stephen BassoChief Financial Officer2026-05-04A93,75000Derivative, Class A CommonForm 4 ↗
Jules HaimovitzDirector2026-05-04A10,00000Derivative, Class A CommonForm 4 ↗
Marianne ZhenChief Accounting Officer2026-05-04A12,76600CommonForm 4 ↗
Pavel RaifeldDirector2026-05-04A126,64600CommonForm 4 ↗
Derek A. SmallDirector2026-05-04A10,00000Derivative, Class A CommonForm 4 ↗
Pavel RaifeldDirector2026-05-04A312,50000Derivative, Class A CommonForm 4 ↗
Mark A. DiPaoloDirector2026-05-04A9,78600CommonForm 4 ↗
Mark A. DiPaoloDirector2026-05-04A10,00000Derivative, Class A CommonForm 4 ↗
Josephine LindenDirector2026-05-18A9,16600Derivative, Class A CommonForm 4 ↗
Josephine LindenDirector2026-05-18A9,46100CommonForm 4 ↗
Josephine LindenDirector2026-05-18A5,73300CommonForm 4 ↗
Stephen BassoChief Financial Officer2026-05-20D5592212,432CommonForm 4 ↗
Marianne ZhenChief Accounting Officer2026-05-20D1,1272225,064CommonForm 4 ↗
Stephen BassoChief Financial Officer2026-05-20A1,12300CommonForm 4 ↗
Pavel RaifeldDirector2026-05-20A1,12300CommonForm 4 ↗
Pavel RaifeldDirector2026-05-20D1,1302225,131CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Marianne ZhenOPTION2025-02-2430,300$229,989
Pavel RaifeldOPTION2025-03-14243,7501,748,882
Pavel RaifeldRSU2025-03-1437,377649,986
Marianne ZhenRSU2025-02-248,938161,599
Stephen BassoRSU2025-11-0327,609499,999
Stephen BassoRSU2025-02-2410,569191,088
Stephen BassoOPTION2025-02-24100,831765,348
Pavel RaifeldRSU2025-11-03110,4361,999,996
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Marianne Zhen$161,599$0$229,9890.0%
Pavel Raifeld2,649,98201,748,8820.0%
Stephen Basso691,0870765,3480.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Pavel RaifeldOption56,25018
Stephen BassoOption14,56814.88
Pavel RaifeldOption243,75017.39
Pavel RaifeldRSU37,377747,166
Marianne ZhenOption30,30018.08
Marianne ZhenRSU8,938178,671
Marianne ZhenOption93718.68
Stephen BassoRSU6,804136,012
Marianne ZhenOption6,25012.2
Stephen BassoOption100,83118.08
Pavel RaifeldRSU110,4362,207,415
Stephen BassoOption75,00012.75
Stephen BassoRSU27,609551,904
Pavel RaifeldOption42,18714.88
Stephen BassoRSU10,569211,274
Pavel RaifeldOption84,37520
Marianne ZhenRSU6,048120,900
Pavel RaifeldOption18,75016.31
Marianne ZhenOption12,94914.88
Marianne ZhenRSU4,48289,595
Marianne ZhenRSU4188,356
05

Incentive-plan design — the Compensation Discussion & Analysis

The primary goals of our executive compensation programs are to (i) fairly compensate and reward executives for performance, (ii) attract and retain highly qualified executives, and (iii) align executives long-term interests with those of our stockholders.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantMeridian
Clawback policyTrue
Anti-hedging
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-0456,243,8802,836,001158,04694.95%Passed
20252025-05-1945,767,6492,070,275187,65295.3%Passed
20242024-06-1752,833,1501,146,78819,57597.84%Passed
20232023-05-2251,955,2752,512,79531,01095.39%Passed
20222022-04-2551,473,5401,726,447104,54296.57%Passed
20212021-05-1448,107,04535,542,106134,97057.42%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-0494.95%a
20252025-05-1995.3%b
20242024-06-1797.84%c

a. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.”.

b. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.”.

c. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)12.3 : 1
CEO total compensation$5,400,197
Median employee compensation$437,552
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jules HaimovitzIndependent$150,000$224,995$72,241$447,236
Mark A. DiPaoloIndependent105,838224,99572,241403,074
Sarah J. SchlesingerIndependent99,615224,99572,241396,851
Derek A. SmallIndependent86,634224,99572,241383,870
Sapna SrivastavaIndependent32,69232,692
Odysseas D. KostasIndependent19,23119,231
09

Board fee structure and ownership guideline

Annual cash retainer
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)
Stock ownership guidelinebeginning after five years of service, non-employee directors are expected to hold shares...with a value equal to at least ten times their annual base cash retainer.
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$494,010
Equity awards (grant-date value)$899,980
All other compensation$0
Total cost of the board$1,393,990

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Innoviva names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Innoviva.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Cogent Biosciences, Inc.2025Andrew Robbins$724,554$12,993,250$13,447,680$561,600$27,762,684
2SpringWorks Therapeutics, Inc.2024Saqib Islam760,0007,899,7606,689,100798,00016,153,317
3Ligand Pharmaceuticals Inc.2025Todd Davis724,5005,520,4934,441,120764,40011,472,095
4Morphic Holding, Inc.2023Praveen Tipirneni613,5023,742,9604,121,756412,9668,907,684
5Travere Therapeutics, Inc.2025Eric Dube854,2503,314,5203,309,384964,1258,457,151
6Catalyst Pharmaceuticals, Inc.2024Richard Daly750,0001,267,6015,070,83007,774,160
7Arvinas, Inc.2025John Houston706,2362,685,8402,671,051457,0006,534,127
8Xencor, Inc.2025Bassil Dahiyat742,8001,552,8922,727,018490,2485,521,205
9Innoviva2025Pavel Raifeld600,0002,649,9821,748,88205,400,197
10Agios Pharmaceuticals, Inc.2025Brian Goff846,8641,291,6802,627,252592,8045,370,389
11Xeris Biopharma Holdings, Inc.2025John Shannon742,3342,848,000838,615607,9715,042,584
12Savara Inc.2025Matthew Pauls660,0003,870,0000297,0004,845,000
13Amarin Corporation plc2025Aaron Berg725,6671,391,250493,975588,3003,540,366
14Coherus BioSciences, Inc.2025Dennis Lanfear1,026,5450828,130869,2952,736,874
15MacroGenics, Inc.2025Eric Risser561,56852,0001,049,386251,9002,078,854
16Theravance Biopharma, Inc.2025Rick Winningham1,047,43100419,1821,472,019
Verona Pharma plcnot in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Innoviva105%not disclosednot disclosedMeridian
Agios Pharmaceuticals, Inc.100%Options 40 · PSU 40 · RSU 20NoAon
Amarin Corporation plc107.75%Options 75 · RSU 25not disclosedPearl Meyer
Arvinas, Inc.108%Options 50 · RSU 50not disclosedAon (Aon's Human Capital Solutions practice, a division of Aon plc)
Catalyst Pharmaceuticals, Inc.105%not disclosednot disclosedMercer LLC (a business of Marsh McLennan)
Cogent Biosciences, Inc.135%not disclosedNoCompensia
Coherus BioSciences, Inc.not disclosedOptions 100not disclosedAon
Ligand Pharmaceuticals Inc.150%Options 44 · PSU 31 · RSU 25NoAon (Talent Solutions practice)
MacroGenics, Inc.85%not disclosednot disclosedAlpine Rewards, LLC
Morphic Holding, Inc.120%RSU 50 · Options 50not disclosedAon
Savara Inc.90%RSU 100not disclosedAon
SpringWorks Therapeutics, Inc.140%not disclosedYes — Relative Total Shareholder Return (TSR)Aon plc (Human Capital Solutions practice)
Theravance Biopharma, Inc.not disclosedRSU 100not disclosedFrederic W. Cook & Co. (FW Cook)
Travere Therapeutics, Inc.150%not disclosedNoAon
Verona Pharma plcnot disclosednot disclosednot disclosednot disclosed
Xencor, Inc.110%Options 60 · RSU 40not disclosedAon
Xeris Biopharma Holdings, Inc.125%not disclosednot disclosedAon Consulting, Inc.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Pavel RaifeldDEF 14A2026-03-240001140361-26-010912Section “Summary Compensation Table”. As printed: 5,400,197. Filing ↗machine: t108 · r1 · c25 · span 555478–555487
2Section 01, Stephen BassoDEF 14A2026-03-240001140361-26-010912Section “Summary Compensation Table”. As printed: 2,171,276. Filing ↗machine: r4 · c25 · span 570932–570941
3Section 01, Marianne ZhenDEF 14A2026-03-240001140361-26-010912Section “Summary Compensation Table”. As printed: 1,082,859. Filing ↗machine: r7 · c25 · span 585299–585308
4Section 03, Marianne Zhen OPTIONDEF 14A2026-03-240001140361-26-010912Section “THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t108 · r7 · c17 · span 583654–583661
5Section 03, Pavel Raifeld OPTIONDEF 14A2026-03-240001140361-26-010912Section “THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t108 · r1 · c17 · span 553831–553840
6Section 03, Pavel Raifeld RSUDEF 14A2026-03-240001140361-26-010912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t112 · r2 · c16 · span 612602–612609
7Section 03, Marianne Zhen RSUDEF 14A2026-03-240001140361-26-010912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t112 · r8 · c16 · span 634200–634207
8Section 03, Stephen Basso RSUDEF 14A2026-03-240001140361-26-010912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t112 · r6 · c16 · span 626285–626292
9Section 03, Stephen Basso RSUDEF 14A2026-03-240001140361-26-010912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t112 · r5 · c16 · span 622980–622987
10Section 03, Stephen Basso OPTIONDEF 14A2026-03-240001140361-26-010912Section “THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t108 · r4 · c17 · span 569591–569598
11Section 03, Pavel Raifeld RSUDEF 14A2026-03-240001140361-26-010912Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t112 · r3 · c16 · span 616592–616601
12Section 07, pay ratioDEF 14A2026-03-240001140361-26-010912Section “CEO Pay Ratio”. As printed: 12.3 : 1. Filing ↗machine: span 872603–872612
13Section 08, Jules HaimovitzDEF 14A2026-03-240001140361-26-010912Section “Director Compensation”. As printed: 447,236. Filing ↗machine: t38 · r4 · c15 · span 205583–205590
14Section 08, Mark A. DiPaoloDEF 14A2026-03-240001140361-26-010912Section “Director Compensation”. As printed: 403,074. Filing ↗machine: t38 · r3 · c15 · span 202145–202152
15Section 08, Sarah J. SchlesingerDEF 14A2026-03-240001140361-26-010912Section “Director Compensation”. As printed: 396,851. Filing ↗
16Section 08, Derek A. SmallDEF 14A2026-03-240001140361-26-010912Section “Director Compensation”. As printed: 383,870. Filing ↗machine: t38 · r7 · c15 · span 214885–214892
17Section 08, Sapna SrivastavaDEF 14A2026-03-240001140361-26-010912Section “Director Compensation”. As printed: 32,692. Filing ↗
18Section 08, Odysseas D. KostasDEF 14A2026-03-240001140361-26-010912Section “Director Compensation”. As printed: 19,231. Filing ↗
19Section 02, Derek A. Small 2026-05-04Form 42026-05-060001193125-26-209003Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Sarah J. Schlesinger 2026-05-04Form 42026-05-060001193125-26-209006Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Jules Haimovitz 2026-05-04Form 42026-05-060001193125-26-209001Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Stephen Basso 2026-05-04Form 42026-05-060001193125-26-209005Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Sarah J. Schlesinger 2026-05-04Form 42026-05-060001193125-26-209006Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Marianne Zhen 2026-05-04Form 42026-05-060001193125-26-209007Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Stephen Basso 2026-05-04Form 42026-05-060001193125-26-209005Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Jules Haimovitz 2026-05-04Form 42026-05-060001193125-26-209001Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Marianne Zhen 2026-05-04Form 42026-05-060001193125-26-209007Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Pavel Raifeld 2026-05-04Form 42026-05-060001193125-26-209009Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Derek A. Small 2026-05-04Form 42026-05-060001193125-26-209003Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Pavel Raifeld 2026-05-04Form 42026-05-060001193125-26-209009Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Mark A. DiPaolo 2026-05-04Form 42026-05-060001193125-26-209015Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Mark A. DiPaolo 2026-05-04Form 42026-05-060001193125-26-209015Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Josephine Linden 2026-05-18Form 42026-05-200001193125-26-232638Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Josephine Linden 2026-05-18Form 42026-05-200001193125-26-232638Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Josephine Linden 2026-05-18Form 42026-05-200001193125-26-232638Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Stephen Basso 2026-05-20Form 42026-05-220001193125-26-236913Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Marianne Zhen 2026-05-20Form 42026-05-220001193125-26-236907Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Stephen Basso 2026-05-20Form 42026-05-220001193125-26-236913Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Pavel Raifeld 2026-05-20Form 42026-05-220001193125-26-236910Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Pavel Raifeld 2026-05-20Form 42026-05-220001193125-26-236910Insider equity transaction reported since the proxy statement. Filing ↗
41Section 06, 2026 voteForm 8-K2026-05-040001193125-26-204243Item 5.07 · say-on-pay result. As reported: 94.95% (votes for as printed: 56,243,880). Filing ↗
42Section 06, 2025 voteForm 8-K2025-05-210001104659-25-051614Item 5.07 · say-on-pay result. As reported: 95.3% (votes for as printed: 45,767,649). Filing ↗
43Section 06, 2024 voteForm 8-K2024-06-200001104659-24-073416Item 5.07 · say-on-pay result. As reported: 97.84% (votes for as printed: 52,833,150). Filing ↗
44Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
45Section 09b board cost (computed)ComputedcomputedCash 494,010 + equity 899,980 + all other 0 = 1,393,990, summed across the director compensation table rows.machine: formula: Σ = 1,393,990
46Cogent Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173834CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363
47SpringWorks Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-040001104659-25-032187CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. Filing ↗machine: t23 · r1 · c44 · span 623184–623194
48Ligand Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-210000886163-26-000021CEO total compensation as printed in Ligand Pharmaceuticals Inc.'s own proxy. As printed: 11,472,095. Filing ↗machine: span 722741–722751
49Morphic Holding, Inc., Section 10b CEO totalDEF 14A2024-04-250001679363-24-000035CEO total compensation as printed in Morphic Holding, Inc.'s own proxy. As printed: 8,907,684. Filing ↗machine: r3 · c48 · span 295049–295058
50Travere Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-060001438533-26-000027CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523
51Catalyst Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-110001193125-25-079097CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗machine: r3 · c31 · span 285833–285842
52Arvinas, Inc., Section 10b CEO totalDEF 14A2026-04-290001628280-26-028156CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930
53Xencor, Inc., Section 10b CEO totalDEF 14A2026-04-270001326732-26-000031CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334
54Innoviva (subject), Section 10b CEO totalDEF 14A2026-03-240001140361-26-010912CEO total compensation as printed in Innoviva's own proxy. As printed: 5,400,197. Filing ↗machine: t108 · r1 · c25 · span 555478–555487
55Agios Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177086CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194
56Xeris Biopharma Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-230001867096-26-000021CEO total compensation as printed in Xeris Biopharma Holdings, Inc.'s own proxy. As printed: 5,042,584. Filing ↗machine: r3 · c42 · span 463532–463541
57Savara Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177353CEO total compensation as printed in Savara Inc.'s own proxy. As printed: 4,845,000. Filing ↗machine: r2 · c30 · span 340387–340396
58Amarin Corporation plc, Section 10b CEO totalDEF 14A2026-04-100001193125-26-151417CEO total compensation as printed in Amarin Corporation plc's own proxy. As printed: 3,540,366. Filing ↗machine: r2 · c30 · span 991658–991667
59Coherus BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045251CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. Filing ↗machine: t112 · r5 · c14 · span 540087–540096
60MacroGenics, Inc., Section 10b CEO totalDEF 14A2026-04-080001125345-26-000021CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198
61Theravance Biopharma, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050454CEO total compensation as printed in Theravance Biopharma, Inc.'s own proxy. As printed: 1,472,019. Filing ↗machine: r1 · c41 · span 475558–475567
62Section 10a, MacroGenics, Inc. reciprocityDEF 14A0001125345-26-000021MacroGenics, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
63Section 10a, Agios Pharmaceuticals, Inc. reciprocityDEF 14A0001193125-26-177086Agios Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
64Section 10a, Coherus BioSciences, Inc. reciprocityDEF 14A0001104659-26-045251Coherus BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
65Section 10a, SpringWorks Therapeutics, Inc. reciprocityDEF 14A0001104659-25-032187SpringWorks Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
66Section 10a, Cogent Biosciences, Inc. reciprocityDEF 14A0001193125-26-173834Cogent Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
67Section 10a, Morphic Holding, Inc. reciprocityDEF 14A0001679363-24-000035Morphic Holding, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
68Section 10a, Travere Therapeutics, Inc. reciprocityDEF 14A0001438533-26-000027Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
69Section 10a, Savara Inc. reciprocityDEF 14A0001193125-26-177353Savara Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
70Section 10a, Ligand Pharmaceuticals Inc. reciprocityDEF 14A0000886163-26-000021Ligand Pharmaceuticals Inc. names Innoviva in its own disclosed peer group (read from its most recent proxy). Filing ↗
71Section 10a, Xeris Biopharma Holdings, Inc. reciprocityDEF 14A0001867096-26-000021Xeris Biopharma Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
72Section 10a, Amarin Corporation plc reciprocityDEF 14A0001193125-26-151417Amarin Corporation plc's most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
73Section 10a, Arvinas, Inc. reciprocityDEF 14A0001628280-26-028156Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
74Section 10a, Catalyst Pharmaceuticals, Inc. reciprocityDEF 14A0001193125-25-079097Catalyst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗
75Section 10a, Xencor, Inc. reciprocityDEF 14A0001326732-26-000031Xencor, Inc.'s most recent proxy was read; its disclosed peer group does not include Innoviva. Filing ↗